Expert Speakers include:

Addressing the multi-faceted challenges of the off-patent drug industry to ensure company profitability, consumer safety and realizing the demand for affordable healthcare

The global generics market is forecast to be valued at $183.2 billion by 2014, with Asia Pacific accounting for 36.2% of the global generics market. (companiesandmarkets.com)

With strong demand for affordable healthcare throughout Asia governments are favoring the production and prescription of generics and biosimilars. The Generics & Biosimilars Asia 2011 conference is set to address many of the pressing issues faced by both innovator and generic drug companies. Attendees will be able to network and learn from peers facing similar challenges in market access, drug pricing and reimbursement in the evolving pharmaceutical industry in Asia.

Key themes for Generics & Biosimilars 2011:

  • Latest development of regulatory guidelines for the registration of generics and biosimilars in Asia and Europe
  • Evaluating how reimbursement policies can affect your drug pricing strategies
  • Examining how strategic alliances affect R&D, innovation and market positioning of your products
  • The key challenges in marketing and distributing innovative drugs alongside generics in Asia
  • Overcoming the challenges of the biosimilars industry
  • Pharmacovigilance for generics and biosimilars: how can consumers’ health be safeguarded?

Don’t miss out on these expert-led workshops on 2nd March 2011:

  • Workshop A: Implementation of Quality by Design (QbD) for Generics
    By Jack Aurora
    Chief Scientifi c Offi cer and R&D Director
    Hisun Pharmaceuticals
  • Workshop B: Legal considerations and challenges for pharmaceutical sourcing and contractin
    By Tony Yeo
    Director, Biomedical Sciences Group
    Drew & Napier LLC
Endorser Marketing partner
logo_TGPA GII_logo
Media Partners
Mediapatners

[ Register Now ]